

Clinical trials of dapagliflozin

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
dapagliflozin vs			
Yang , 2015 [NCT01095666] n=NA follow-up:	-	-	China
dapagliflozin vs dlipizide add on metformin			
Nauck , 2011 [NCT00660907] n=NA follow-up:	Dapagliflozin in Combination With Metformin versus Sulphonylurea in Combination With Metformin	Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone	
dapagliflozin vs placebo			
Kohan [NCT00972244] n=NA follow-up:	Dapagliflozin as Monotherapy versus placebo	Japanese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control	
Kaku , 2014 [NCT01294423] n=NA follow-up: 24 w	-	-	Japan
Ferrannini (MB102013) , 2010 [NCT00528372] n=NA follow-up: 24 weeks	a morning dose of 5 or 10 mg/day dapagliflozin versus placebo	treatment-naive patients with type 2 diabetes	double-blind
Komoroski (MB102007) , 2009 [NCT00162305] n=NA follow-up: 14 days	daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin versus placebo	patients with type 2 diabetes mellitus	

continued...

Trial	Treatments	Patients	Trials design and methods
List (MB102008) , 2009 [NCT00263276] n=NA follow-up: 12 weeks	one of five dapagliflozin doses versus placebo	type 2 diabetic patients	
Kohan [NCT00663260] n=NA follow-up:	Dapagliflozin versus placebo	Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Contro	
KOhan [NCT00736879] n=NA follow-up:	Dapagliflozin monotherapy versus placebo	-	
DECLARE TIMI 58 <i>ongoing</i> [NCT01730534] n=NA follow-up:	-	-	
DERIVE <i>ongoing</i> [NCT02413398] n=NA follow-up: 24 w	Dapagliflozin (10 mg Tablets, Oral, Once daily, 24 weeks) versus Placebo	patients with Type 2 diabetes and moderate renal impairment	USA
MB102-210 <i>ongoing</i> [NCT02383238] n=NA follow-up:	-	-	
DECLARE-TIMI 58 <i>ongoing</i> [NCT01730534] n=NA follow-up:	Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors versus Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors	-	
D1693C00002 <i>ongoing</i> [NCT01257412] n=NA follow-up:	-	-	India

continued...

Trial	Treatments	Patients	Trials design and methods
D1690C00023 <i>ongoing</i> [NCT02547935] n=NA follow-up:	-	-	USA
dapagliflozin vs placebo (add on insulin)			
Wilding , 2012 [NCT00673231] n=NA follow-up:	Dapagliflozin versus placebo on top of insulin	Type 2 Diabetes With Inadequate Glycaemic Control on Insulin	
Wilding (MB102009) , 2009 [NCT00357370] n=NA follow-up: 12 weeks	10 mg dapagliflozin, or 20 mg dapagliflozin, plus OAD(s) and 50% of their daily insulin dose versus placebo	patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents	double-blind US, Canada
dapagliflozin vs placebo (add on MET + SAXA)			
Mathieu , 2015 [NCT01646320] n=NA follow-up: 24 w	-	-	USA
dapagliflozin vs placebo (add on MET)			
Bailey (MB102014) , 2010 [NCT00528879] n=NA follow-up: 24 weeks	dapagliflozin (25 mg, n=137; 5 mg, n=137; or 10 mg, n=135) versus placebo	adults with type 2 diabetes who were receiving daily metformin (1500 mg per day) and had inadequate glycaemic control	Parallel groups double-blind
Bolinder , 2012 [NCT00855166] n=NA follow-up:	dapagliflozin versus placebo or Sitagliptin (on top MET)	-	
Schumm-Draeger , 2015 [NCT01217892] n=NA follow-up:	Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD versus placebo	Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy	
dapagliflozin vs placebo (add on MET+SU)			
Matthaei , 2015 [NCT01392677] n=NA follow-up:	-	-	Canada
dapagliflozin vs placebo (add on TZD)			

continued...

Trial	Treatments	Patients	Trials design and methods
Rosenstock , 2012 [NCT00683878] n=NA follow-up:	Dapagliflozin in Combination With Thiazolidinedione versus Thiazolidinedione	Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone	
dapagliflozin vs placebo (on top standard treatment)			
Leiter , 2016 [NCT01042977] n=NA follow-up:	Dapagliflozin 10 mg tablet, oral, once daily, 24- week treatment versus placebo	Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care	
MB102035 [NCT00976495] n=NA follow-up:	Dapagliflozin Tablets, Oral, 10 mg, once daily, 12 weeks versus placebo	-	
Cefalu , 2015 [NCT01031680] n=NA follow-up:	Dapagliflozin 10 mg tablet, oral, once daily, 24- week versus placebo	-	
MB102073 [NCT01137474] n=NA follow-up:	Dapagliflozin Tablets, Oral, 10 mg, once daily, up to 12 weeks versus placebo	patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin Receptor Blocker (ARB).	
Weber [NCT01195662] n=NA follow-up:	Dapagliflozin Tablets, Oral, 10 mg, once daily, Up to 12 weeks versus placebo	Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication	
dapagliflozin vs placebo add on DPP-4			
MB102061 [NCT00984867] n=NA follow-up:	Dapagliflozin 10 mg tablet, oral, once daily, 48 weeks versus placebo	Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin	
dapagliflozin vs Saxagliptin (add on MET)			
Rosenstock , 2015 [NCT01606007] n=NA follow-up: 24 w	-	-	USA

continued...

Trial	Treatments	Patients	Trials design and methods
CV181-365 <i>ongoing</i> [NCT02419612] n=NA follow-up: 52 w	-	-	USA
dapagliflozin vs dapagliflozin			
D1695C00001 <i>ongoing</i> [NCT02582814] n=NA follow-up:	dapagliflozin 5mg versus dapagliflozin 10mg	-	Japan
Saxagliptin/Dapagliflozin vs Glargine insulin			
CV181-369 <i>ongoing</i> [NCT02551874] n=NA follow-up:	-	-	USA
dapagliflozin vs placebo (add on EXE)			
D5553C00003 <i>ongoing</i> [NCT02229396] n=NA follow-up: 24 w	Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg () versus Exenatide Once Weekly 2 mg Alone ()	-	USA
dapagliflozin vs placebo (add on INS)			
MB102-137 <i>ongoing</i> [NCT02096705] n=NA follow-up: 24 w	-	-	China
dapagliflozin vs placebo (add on SAXA + MET)			
D1683C00005 <i>ongoing</i> [NCT02681094] n=NA follow-up: 24 w	Saxagliptin+Dapagliflozin+Metformin (5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin) versus Saxagliptin+Dapagliflozin placebo+metformin (5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo)	patients who are inadequately controlled on 1500mg/day of metformin monotherapy	USA
dapagliflozin vs placebo (add-on MET)			
MB102-054 <i>ongoing</i> [NCT01095653] n=NA follow-up:	-	-	China

continued...

Trial	Treatments	Patients	Trials design and methods
dapagliflozin vs saxa (add on MET)			
CV181-363 <i>ongoing</i> [NCT02284893] n=NA follow-up: 26 w	-	-	USA
dapagliflozin vs Sitagliptin (add on mET)			
0431-838 <i>ongoing</i> [NCT02532855] n=NA follow-up: 24 w	-	Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin	USA
dapagliflozin + merformin vs dapagliflozin			
Kohan [NCT00643851] n=NA follow-up:	Dapagliflozin in Combination With Metformin versus Dapagliflozin Monotherapy	Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control	
dapagliflozin + Glimepiride vs glimepiride			
Strojek , 2011 [NCT00680745] n=NA follow-up:	Dapagliflozin in Comb.With Glimepiride versus glimepiride alone	Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone	
dapagliflozin + merformin vs metformin or dapa			
MB102034 , 2016 [NCT00859898] n=NA follow-up:	Dapagliflozin 10 mg in Combination With Metformin versus Dapagliflozin 10 mg Monotherapy or Metformin Monotherapy	Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control	

More details and results :

- SGLT2 inhibitors for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q479>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>

References

Yang, 2015:

Yang W, Han P, Min KW, Wang B, Mansfield T, T'Joel C, Iqbal N, Johnsson E, Ptaszynska A Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial. *J Diabetes* 2015;: [26589253]

Nauck, 2011:

Nauck MA, Del Prato S, Meier JJ, Durn-Garca S, Rohwedder K, Elze M, Parikh SJ Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glyceemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. *Diabetes Care* 2011 Sep;34:2015-22 [21816980]

Nauck M, del Prato S, Meier JJ, Durn-Garca S, Rohwedder K, Elze M, Parikh SJ [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glyceemic control with metformin]. *Dtsch Med Wochenschr* 2013;138 Suppl 1:S6-15 [23529570]

Kohan, :

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [26894924]

Kaku, 2014:

Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, Langkilde AM Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. *Diabetes Obes Metab* 2014;16:1102-10 [24909293]

Ferrannini (MB102013), 2010:

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glyceemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* 2010;33:2217-24. [20566676] [10.2337/dc10-0612](https://doi.org/10.2337/dc10-0612)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [26894924]

Komoroski (MB102007), 2009:

Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M, Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glyceemic control over 2 weeks in patients with type 2 diabetes mellitus. *Clin Pharmacol Ther* 2009;85:513-9. [19129749] [10.1038/clpt.2008.250](https://doi.org/10.1038/clpt.2008.250)

List (MB102008), 2009:

List JF, Woo V, Morales E, Tang W, Fiedorek FT, Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care* 2009;32:650-7. [19114612] [10.2337/dc08-1863](https://doi.org/10.2337/dc08-1863)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [26894924]

Kohan, 0:

Kohan DE, Fioretto P, Tang W, List JF Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glyceemic control. *Kidney Int* 2014;85:962-71 [24067431]

KOhan, 0:

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [26894924]

DECLARE TIMI 58, :

ongoing trial NCT01730534

DERIVE, 0:

ongoing trial NCT02413398

MB102-210, 0:

ongoing trial NCT02383238

DECLARE-TIMI 58, 0:

ongoing trial NCT01730534

D1693C00002, 0:

ongoing trial NCT01257412

D1690C00023, 0:

ongoing trial NCT02547935

Wilding, 2012:

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. *Ann Intern Med* 2012;156:405-15 [22431673] [10.1059/0003-4819-156-6-201203200-00003](https://doi.org/10.1059/0003-4819-156-6-201203200-00003)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [26894924]

van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M Cost effectiveness of adding dapagliflozin to insulin for the treatment of type2 diabetes mellitus in the Netherlands. *Clin Drug Investig* 2014;34:135-46 [24243529]

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. *Diabetes Obes Metab* 2014;16:124-36 [23911013]

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin]. *Dtsch Med Wochenschr* 2013;138 Suppl 1:S27-38 [23529568]

Wilding (MB102009), 2009:

Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT, A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. *Diabetes Care* 2009;32:1656-62. [19528367] [10.2337/dc09-0517](https://doi.org/10.2337/dc09-0517)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [26894924]

Mathieu, 2015:

Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, Chen H, Hansen L, Iqbal N Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. *Diabetes Care* 2015;38:2009-17 [26246458]

Bailey (MB102014), 2010:

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet* 2010 Jun 26;375:2223-2233 [20609968] [10.1016/S0140-6736\(10\)60407-2](https://doi.org/10.1016/S0140-6736(10)60407-2)

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF, Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet* 2010;375:2223-33. [20609968] [10.1016/S0140-6736\(10\)60407-2](https://doi.org/10.1016/S0140-6736(10)60407-2)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016;: [26894924]

Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:43 [23425012]

Bolinder, 2012:

Bolinder J, Ljunggren , Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glyceemic control on metformin. J Clin Endocrinol Metab 2012 Mar;97:1020-31 [22238392]

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016;: [26894924]

Bolinder J, Ljunggren , Johansson L, Wilding J, Langkilde AM, Sjstrm CD, Sugg J, Parikh S Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16:159-69 [23906445]

Ljunggren , Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjstrm CD, Sugg J, Parikh S Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9 [22651373]

Schumm-Draeger , 2015:

Schumm-Draeger PM, Burgess L, Kornyi L, Hrubá V, Hamer-Maansson JE, de Bruin TW Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes Obes Metab 2015;17:42-51 [25200570]

Matthaei, 2015:

Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S Dapagliflozin improves glyceemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care 2015;38:365-72 [25592197]

Rosenstock, 2012:

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016;: [26894924]

Rosenstock J, Vico M, Wei L, Salsali A, List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8 [22446170]

Leiter, 2016:

Leiter LA, Cefalu WT, de Bruin TW, Xu J, Parikh S, Johnsson E, Gause-Nilsson I Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab 2016;: [27009868]

MB102035, :

Cefalu, 2015:

Leiter LA, Cefalu WT, de Bruin TW, Xu J, Parikh S, Johnsson E, Gause-Nilsson I Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab 2016;: [27009868]

Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care 2015;38:1218-27 [25852208]

MB102073, :

Weber, :

Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Diabetes Endocrinol* 2016;4:211-20 [[26620248](#)]

MB102061, :**Rosenstock, 2015:**

Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, Iqbal N Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. *Diabetes Care* 2015;38:376-83 [[25352655](#)]

CV181-365, 0:

ongoing trial NCT02419612

D1695C00001, 0:

ongoing trial NCT02582814

CV181-369, 0:

ongoing trial NCT02551874

D5553C00003, 0:

ongoing trial NCT02229396

MB102-137, 0:

ongoing trial NCT02096705

D1683C00005, 0:

ongoing trial NCT02681094

MB102-054, 0:

ongoing trial NCT01095653

CV181-363, 0:

ongoing trial NCT02284893

0431-838, 0:

ongoing trial NCT02532855

Kohan, 0:

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [[26894924](#)]

Strojek, 2011:

Strojek K, Yoon KH, Hrubá V, Elze M, Langkilde AM, Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. *Diabetes Obes Metab* 2011;13:928-38 [[21672123](#)] [10.1111/j.1463-1326.2011.01434.x](#)

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol* 2016;: [[26894924](#)]

Strojek K, Yoon KH, Hrubá V, Elze M, Langkilde AM, Parikh S [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride]. *Dtsch Med Wochenschr* 2013;138 Suppl 1:S16-26 [[23529567](#)]

MB102034, 2016:

Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L The effect of dapagliflozin on renal function in patients with type 2 diabetes. J Nephrol 2016;: [26894924]

Entry terms: saxagliptin, saxagliptin, Onglyza, BMS 477118, BMS477118, BMS-477118, , dapagliflozin, forxiga, BMS 512148, BMS512148, BMS-512148,